@article{00cb4d67111e44a587d0e533817ff2b5,
title = "Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events",
abstract = "In this analysis of a phase III trial in patients with castration-resistant prostate cancer and bone metastases, treatment with denosumab reduced the risk of skeletal complications vs zoledronic acid regardless of whether the end point was defined as SSE or SRE. Both SSEs and SREs were associated with development of moderate/severe pain among patients with no/mild pain at baseline.",
keywords = "Denosumab, Phase III, Prostate cancer, Skeletal-related events, Symptomatic skeletal events, Zoledronic acid",
author = "Smith, {Matthew R.} and Coleman, {R. E.} and L. Klotz and K. Pittman and P. Milecki and S. Ng and Chi, {K. N.} and A. Balakumaran and R. Wei and H. Wang and A. Braun and K. Fizazi",
note = "Publisher Copyright: {\textcopyright} The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.",
year = "2015",
month = feb,
day = "1",
doi = "10.1093/annonc/mdu519",
language = "English",
volume = "26",
pages = "368--374",
journal = "Annals of Oncology",
issn = "0923-7534",
number = "2",
}